<DOC>
	<DOCNO>NCT00362024</DOCNO>
	<brief_summary>MK0952 phosphodiesterase type IV ( PDE4 ) inhibitor development improvement cognitive impairment mild-to-moderate Alzheimer 's disease .</brief_summary>
	<brief_title>MK0952 Patients With Mild-to-Moderate Alzheimer 's Disease ( 0952-004 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Male female Age &gt; /= 55 year , With mildtomoderate AD , MMSE 18 26 , inclusive , MHIS score &lt; /= 4 , Global CDR score 1 2 Who reliable informant/caregiver accompany patient clinic visit If use symptomatic AD treatment , patient must stable dose &gt; /= 6 month Patients must live nursing home skilled nursing facility Patients must current evidence and/or history Crohn 's disease , ulcerative colitis , proctitis , GI bleeding , mesenteric arteritis Patients must current evidence and/or history poorlycontrolled hypertension , clinically significant cardiac arrhythmia , angina , CHF Patients must current evidence and/or history psychotic disorder major untreated depressive disorder Patients must current evidence and/or history stroke multiple lacunar infarct , neurological neurodegenerative disorder ( AD ) Various concomitant therapy restriction</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>